GlassScriptPhysician profile
Mackenzie C Holm
NPI 1720618135
$5,654.32
in general payments reported to CMS, 2019-2025
27 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,581 · 2022: $1,845 · 2023: $44.23 · 2024: $43.93 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.24 | 2021-2025 | |
| Validus Pharmaceuticals LLC | $476.58 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $466.26 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $404.22 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $404.05 | 2021-2022 | |
| Alkermes, INC. | $403.57 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $372.64 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $293.79 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $228.08 | 2021-2022 | |
| Indivior INC. | $210.59 | 2021-2024 | Sublocade |
| Avanir Pharmaceuticals, INC. | $208.36 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $201.03 | 2021-2022 | |
| Eisai INC. | $174.05 | 2021-2022 | |
| Bausch Health US, LLC | $151.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $130.79 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $126.55 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $111.40 | 2021 | |
| Almatica Pharma LLC | $110.36 | 2021-2022 | |
| Lundbeck LLC | $104.01 | 2021-2022 | |
| Noven Therapeutics, LLC | $90.99 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $47.88 | 2022 | |
| Uswm, LLC | $47.24 | 2021-2022 | |
| Adlon Therapeutics L.P. | $31.50 | 2021 | |
| Ironshore Pharmaceuticals INC. | $23.02 | 2021 | |
| Pfizer INC. | $22.33 | 2025 | |
| Owp Pharmaceuticals, INC. | $15.54 | 2022 | |
| Gilead Sciences, INC. | $14.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Holm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.